APIXABAN 2.5 MG/ 5 MG FILM COATED TABLETS

Product Information

Therapeutic indications: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Pharmacotherapeutic group:Direct factor Xa inhibitors.
Pack style: 10 x 10 Tablets or as per customer specification.

HYDROXYCHLOROQUINE SULPHATE 300 MG TABLETS

Product Information

Therapeutic indications:
Adults: Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight.
Paediatric population: Treatment of juvenile idiopathic arthritis (in combination with other therapies), discoid and systemic lupus erythematosus.

Pharmacotherapeutic group: Anti -rheumatic
Pack style: 10 x 10 Tablets or as per customer specification

MONTELUKAST SODIUM 4/5/10 MG FILM COATED TABLETS

Product Information

Therapeutic indicationsMontelukast film-coated tablets is indicated in the treatment of in mild to moderate asthma inadequately controlled by inhaled corticosteroids and short active B2 agonist, Exercise induced bronchoconstriction.

Pharmacotherapeutic group: Other systemic drugs for obstructive airway diseases, Leukotriene receptor antagonist
Pack style: 30 Tablets or as per customer specification

PACLITAXEL INJECTION USP (100 MG/16.7 ML) / (300 MG/50 ML)

Product Information

Therapeutic indications For the treatment of Breast cancer after failure of combination therapy metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Pharmacotherapeutic group: Oral Rehydration Salts ORS 20.6g
Pack style: 100 mg/16.7 ml , 300 mg/50 ml

RIVAROXABAN 15 MG / 20 MG FILM COATED TABLETS

Product Information

Therapeutic indications 1. Treatment of deep vein thrombosis and for prevention of recurrent DVT and pulmonary embolism.
2. For the prevention of stroke and systemic embolism in patient with non-valvular arterial fibrillation.

Pharmacotherapeutic group: Direct factor Xa inhibitors.
Pack style: 28 Tablets or as per customer specification

RUXOLITINIB 5/15/20 MG TABLETS

Product Information

Therapeutic indications For the treatment of patients with myelofibrosis including primary myelofibrosis, post-polycythemia veramyelofibrosis or post-essential thrombocythemiamyelofibrosis.

Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors
Pack style: 56 Tablets or as per customer specification

SAROGLITAZAR 2 MG/ 4 MG TABLETS

Product Information

Therapeutic indications For the treatment of diabetic dyslipidemia and hypertriglyceridemia with type-2 diabetes mellitus not controlled by statin therapy.

Mechanism of action

Saroglitazar is a potent and predominantly Peroxisome Proliferator Activated Receptor (PPAR)-alpha agonist with moderate PPAR-gamma agonistic activity.

Pack style: 1 x 10 tablets or as per customer specification

TOLTERODINE TARTRATE EXTENDED RELEASE TABLETS 2 MG/ 4 MG

Product Information

Tolterodine Tartrate Tablet acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors.

Therapeutic indications

For the treatment of overactive bladder with symptoms of urge urinary incontinence, urinary incontinence, urgency and frequency.

Pharmacotherapeutic group: Antagonizes muscarinic receptor, which mediates urinary bladder contraction
Pack style: 56 Film coated Tablets or as per customer specification.